Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ZIOPHARM Oncology, Inc.    ZIOP

ZIOPHARM ONCOLOGY, INC.

(ZIOP)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Ziopharm in Supply Agreement with Regeneron to Study Glioblastoma Treatment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/12/2018 | 08:15am EST

By Michael Dabaie

Ziopharm Oncology said Monday it is in a clinical supply agreement with Regeneron Pharmaceuticals to evaluate Ziopharm's Ad-RTS-hIL-12 plus veledimex in combination with Regeneron's Libtayo to treat patients with recurrent glioblastoma.

Ziopharm and Regeneron will initiate a Phase 2 study in the first half of 2019 to measure preliminary safety and efficacy of Ad-RTS-hIL-12 plus veledimex in combination with Libtayo. Ziopharm will be responsible for the conduct and costs of the clinical trial, and Regeneron will supply Libtayo for the study. The companies potentially could explore additional indications.

Ad-RTS-hIL-12 plus veledimex is an investigational gene therapy to induce and control the production of human interleukin 12 that activates the immune system and recruits cancer-fighting T cells into tumors. Libtayo has been approved in the U.S. to treat patients with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who aren't candidates for curative surgery or radiation.

Ziopharm shares were up 2% to $2.56 premarket.

Write to Michael Dabaie at michael.dabaie@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS 1.06% 372.26 Delayed Quote.-0.33%
RUSLAND-RTS 1.25% 1448.34 End-of-day quote.35.44%
ZIOPHARM ONCOLOGY, INC. 1.38% 5.16 Delayed Quote.175.94%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIOPHARM ONCOLOGY, INC.
12/08Ziopharm Oncology Presents Pre-Clinical Data Validating “Rapid Persona..
GL
11/25ZIOPHARM ONCOLOGY INC : Regulation FD Disclosure, Other Events, Financial Statem..
AQ
11/25ZIOPHARM ONCOLOGY : Presents Encouraging Clinical Data for Controlled IL-12 for ..
AQ
11/23ZIOPHARM ONCOLOGY : Presents Encouraging Clinical Data for Controlled IL-12 for ..
AQ
11/18Ziopharm Oncology Updates Presentation and Webcast Time at the Jefferies 2019..
GL
11/11Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Confer..
GL
11/07ZIOPHARM : 3Q Earnings Snapshot
AQ
11/07ZIOPHARM ONCOLOGY INC : Results of Operations and Financial Condition, Financial..
AQ
11/07ZIOPHARM ONCOLOGY : Management's Discussion and Analysis of Financial Condition ..
AQ
11/07Ziopharm Oncology Reports Third Quarter 2019 Financial Results
GL
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -56,1 M
Net income 2019 -116 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -7,43x
P/E ratio 2020 -15,5x
Capi. / Sales2019 infx
Capi. / Sales2020 infx
Capitalization 926 M
Chart ZIOPHARM ONCOLOGY, INC.
Duration : Period :
ZIOPHARM Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZIOPHARM ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 6,30  $
Last Close Price 5,16  $
Spread / Highest target 45,3%
Spread / Average Target 22,1%
Spread / Lowest Target -22,5%
EPS Revisions
Managers
NameTitle
Laurence James Neil Cooper Chief Executive Officer & Director
David M. Mauney President
Scott L. Tarriff Independent Non-Executive Chairman
Satyavrat Shukla Chief Financial Officer & Executive Vice President
Lynn M. Ferrucci SVP-IT, Human Resources & Administration
Sector and Competitors
1st jan.Capitalization (M$)
ZIOPHARM ONCOLOGY, INC.175.94%926
GILEAD SCIENCES7.24%84 866
VERTEX PHARMACEUTICALS34.72%57 409
REGENERON PHARMACEUTICALS-0.33%40 697
WUXI APPTEC CO., LTD.74.02%21 510
GENMAB51.29%15 541